LOS ANGELES, CA--(Marketwired - Oct 6, 2015) - Endonovo Therapeutics, Inc. (
Immunotronics™, a non-invasive and non-implantable immuno-regulatory device designed to treat inflammatory conditions in vital organs, including acute organ failure;
and Cytotronics™, a proprietary bioelectronic-based method of expanding and manipulating cells for the creation of cell therapies and tissue engineering.
Bioelectronics/Electroceuticals have raised significant attention due to their potential ability in treating a wide array of conditions including heart failure, asthma, diabetes, incontinence and arthritis while reducing unwanted side effects associated with the use of drugs.
Last year the National Institutes of Health (NIH) announced a $248-million effort to map the body's electrical wiring and develop electroceuticals. It will announce this upcoming autumn the first funding from the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. Additionally, DARPA, the Pentagon's blue-skies research arm, will announce the recipients of its $80 million ElectRx initiative, a program that is part of the defense agency's year-old biotech unit designed to advance discoveries that may help wounded warriors and others. GlaxoSmithKline, is leading the private sector's funding of electroceuticals by investing up to $50 million in bioelectronic startups and $5 million more in basic research to map the body's electrical wiring and how it may affect chronic diseases.
Endonovo is concentrating its efforts on inflammatory conditions in vital organs and previously announced it's in the pre-clinical phase of assessing its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver, including fulminant liver failure.
Endonovo Chief Medical Officer, Leonard Makowka, MD, PhD, said, "Making the transition from pharmaceutical based treatment to the use of devices for treatment would be of substantial benefit to not only the patients, but the healthcare system as a whole. One of the considerable advantages of our technology is that unlike neuromodulation-based therapies, our Immunotronic platform is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs."
Research and development of Endonovo's Immunotronic™ technology spans over 20 years and dates back to the National Aeronautics and Space Administration's (NASA) space program where researchers were seeking to develop non-invasive treatments for injuries astronauts might experience during long-term space exploration.
The origin of the Company's Cytotronics™ platform dates back to experiments aboard the Space Shuttle benefiting from over 15 years of private research to advance the technology from basic research conducted at NASA to the current development of large scale methods for cell expansion and manipulation in the creation of cell therapies and tissue engineering.
Endonovo Chief Scientist, Donnie Rudd, PhD. commented, "We have greatly advanced the technology well beyond the original NASA experiments on cell growth. Our Cytotronics platform is not only valuable in expanding cells, such as cord blood cells, but is also particularly suited for tissue engineering applications."
Alan Collier, CEO of Endonovo said, "We have spent the last year evaluating the regenerative medicine landscape, pursuant to how our product best suited all the possible applications of our platforms while strengthening our intellectual property. We are now well positioned as a company to raise capital for advancing and commercializing our bioelectronic approach to regenerative medicine."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.